Table 4.
Univariable and multivariable analysis of factors associated with 30-day all-cause mortality following VRE bloodstream infection
| Patients who died (n = 27) | Patients who survived (n = 66) | Univariable odds ratio | 95% CI | p-value | Multivariable odds ratio | 95% CI | p-value | |
|---|---|---|---|---|---|---|---|---|
| Age, median (IQR), years | 55 (44–65) | 58 (43–66) | 1.00 | 0.97–1.03 | 0.964 | |||
| Male | 15 (56%) | 34 (52%) | 1.18 | 0.48–2.89 | 0.723 | |||
| CDS-VRE, median (IQR) | 1.9 (1.9–3.9) | 1.9 (1.5–3.4) | 1.40 | 0.99–1.96 | 0.055 | 1.38 | 0.96–1.99 | 0.082 |
| Haematological malignancy | 25 (93%) | 56 (85%) | 2.23 | 0.46–10.94 | 0.322 | |||
| AlloBMT | 9 (33%) | 15 (23%) | 1.70 | 0.63–4.56 | 0.291 | |||
| Hypoalbuminemia days†, median (IQR) | 22 (11–30) | 16 (10–23) | 1.05 | 1.00–1.10 | 0.058 | 1.04 | 0.98–1.09 | 0.186 |
| Mucositis grade, median (IQR) | 0 (0–3) | 0 (0–2) | 1.15 | 0.86–1.54 | 0.336 | |||
| Polymicrobial BSI | 7 (26%) | 14 (21%) | 1.30 | 0.46–3.69 | 0.622 | |||
| Neutropenia at time of BSI | 20 (74%) | 55 (83%) | 0.57 | 0.20–1.68 | 0.308 | |||
| Teicoplanin monotherapy | 14 (52%) | 45 (68%) | 0.54 | 0.22–1.38 | 0.200 | 0.57 | 0.20–1.64 | 0.299 |
| ICU 48 h after BSI | 8 (30%) | 5 (8%) | 5.14 | 1.50–17.58 | 0.009 | 4.16 | 1.08–16.00 | 0.038 |
CDS-VRE score Chronic Disease Score specific to VRE, CKD Chronic kidney disease, AML Acute myeloid leukaemia, alloBMT allogeneic bone marrow transplant, BSI Blood stream infection
†In 30 days prior to bloodstream infection